NO20083031L - Tiadiazolderivater som anti-diabetiske agenter - Google Patents

Tiadiazolderivater som anti-diabetiske agenter

Info

Publication number
NO20083031L
NO20083031L NO20083031A NO20083031A NO20083031L NO 20083031 L NO20083031 L NO 20083031L NO 20083031 A NO20083031 A NO 20083031A NO 20083031 A NO20083031 A NO 20083031A NO 20083031 L NO20083031 L NO 20083031L
Authority
NO
Norway
Prior art keywords
compounds
inhibitors
prevention
formula
treatment
Prior art date
Application number
NO20083031A
Other languages
English (en)
Inventor
Gary Mark Coppola
Thalaththani Ralalage Vedananda
James Richard Wareing
Travis Mathew Stams
Sidney Wolf Topiol
Gregory Raymond Bebernitz
David Barnes
Katsumasa Nakajima
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37950917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083031(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20083031L publication Critical patent/NO20083031L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Forbindelser med formelen. er inhibitorer av proteintyrosinfosfataser (PTPaser) og kan således anvendes for behandling av tilstander mediert av PTPase aktivitet. Forbindelsene ifølge oppfinnelsen kan også anvendes som inhibitorer av andre enzymer kjennetegnet ved en fosfotyrosin-bindingsregion slik som SH2 domenet. Følgelig kan forbindelsene med formel (I) anvendes for hindring og/eller behandling av insulinresistens assosiert med fedme, glukoseintoleranse, diabetes mellitus, hypertensjon og iskemiske sykdommer i store og små blodkar, tilstander som ledsager type-2 diabetes, som inkluderer hyperlipidemi, hypertriglyseridemi, aterosklerose, vaskulær restenose, irritabel tarmsyndrom, pankreatitt, adiposecelletumorer og karsinomer slike som liposarkom, dyslipidemi, og andre forstyrrelser hvor insulinresistens er indikert.I tillegg kan forbindelsene ifølge oppfinnelsen anvendes for behandling og/eller hindring av kreft (slik som prostata- eller brystkreft), osteoporose, neurodegenerative og infeksjonssykdommer, og sykdommer som involverer inflammasjon og immunsystemet.
NO20083031A 2005-12-08 2008-07-04 Tiadiazolderivater som anti-diabetiske agenter NO20083031L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74857305P 2005-12-08 2005-12-08
PCT/US2006/046545 WO2007067615A2 (en) 2005-12-08 2006-12-06 Thiadiazole derivatives as antidiabetic agents

Publications (1)

Publication Number Publication Date
NO20083031L true NO20083031L (no) 2008-08-28

Family

ID=37950917

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083031A NO20083031L (no) 2005-12-08 2008-07-04 Tiadiazolderivater som anti-diabetiske agenter

Country Status (26)

Country Link
US (1) US7700633B2 (no)
EP (1) EP1963292B1 (no)
JP (1) JP2009519248A (no)
KR (1) KR20080074969A (no)
CN (1) CN101326173A (no)
AR (1) AR056838A1 (no)
AT (1) ATE546440T1 (no)
AU (1) AU2006321905B2 (no)
BR (1) BRPI0619600A2 (no)
CA (1) CA2629857A1 (no)
CR (1) CR10049A (no)
EC (1) ECSP088506A (no)
ES (1) ES2381280T3 (no)
IL (1) IL191549A0 (no)
MA (1) MA30202B1 (no)
NO (1) NO20083031L (no)
NZ (1) NZ568243A (no)
PE (2) PE20100733A1 (no)
PL (1) PL1963292T3 (no)
PT (1) PT1963292E (no)
RU (1) RU2008127254A (no)
TN (1) TNSN08249A1 (no)
TW (1) TW200732315A (no)
UA (1) UA94724C2 (no)
WO (1) WO2007067615A2 (no)
ZA (1) ZA200804074B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
BRPI0619543A2 (pt) * 2005-12-08 2011-10-04 Novartis Ag derivados de 1,2,5-tiazolidina, composições farmacêuticas contendo os mesmos e referidos usos
KR20080074966A (ko) * 2005-12-08 2008-08-13 노파르티스 아게 1,1,3-트리옥소-1,2,5-티아디아졸리딘 및 ｐｔｐ-ａｓｅ억제제로서의 그의 용도
WO2008067527A1 (en) * 2006-12-01 2008-06-05 Novartis Ag Inhibitors of protein tyrosine phosphatase for the treatment of muscle atrophy and related disorders
AR066820A1 (es) * 2007-06-04 2009-09-16 Novartis Ag Compuestos de tiadiazolidin-3 ona
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US9040525B2 (en) 2010-10-08 2015-05-26 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2012147516A1 (ja) 2011-04-28 2012-11-01 持田製薬株式会社 環状アミド誘導体
AU2017383102B2 (en) * 2016-12-23 2023-05-11 The University Of Queensland Inhibitors of SOX18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases
US20220073493A1 (en) * 2018-12-21 2022-03-10 Crystal Pharma, S.A.U. Process and intermediates for the preparation of voxelotor
AU2020234712A1 (en) * 2019-03-14 2021-09-09 Abbvie Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
GB201915094D0 (en) * 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
CN116194453A (zh) * 2019-12-20 2023-05-30 卡里科生命科学有限责任公司 蛋白质酪氨酸磷酸酶降解剂及其使用方法
CA3211545A1 (en) * 2021-03-11 2022-09-15 Liansheng Li Heterocycles and uses thereof
MX2024005658A (es) * 2021-11-11 2024-08-06 Calico Life Sciences Llc Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos.
AR128417A1 (es) * 2022-02-02 2024-05-08 Nerio Therapeutics Inc Inhibidores de la proteína tirosina fosfatasa y usos de estos
TW202337459A (zh) * 2022-02-02 2023-10-01 美商耐瑞歐醫療公司 蛋白酪胺酸磷酸酶抑制劑及其用途
WO2023150150A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
WO2024059041A1 (en) * 2022-09-13 2024-03-21 Kumquat Biosciences, Inc. Benzo-fused n-heterocycles and uses thereof
WO2024067802A1 (zh) * 2022-09-30 2024-04-04 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途
WO2024141015A1 (en) * 2022-12-30 2024-07-04 Insilico Medicine Ip Limited Protein tyrosine phosphatase inhibitors and uses thereof
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492780B1 (en) 2002-04-03 2011-11-23 Novartis AG 5-substituted 1,1-dioxo-¬1,2,5 thiazolidine-3-one derivatives as ptpase 1b inhibitors
GB0225986D0 (en) * 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
GB0227813D0 (en) 2002-11-29 2003-01-08 Astrazeneca Ab Chemical compounds
ATE432074T1 (de) * 2002-12-30 2009-06-15 Vertex Pharma Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen
WO2005035551A2 (en) * 2003-10-08 2005-04-21 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
KR20080074966A (ko) 2005-12-08 2008-08-13 노파르티스 아게 1,1,3-트리옥소-1,2,5-티아디아졸리딘 및 ｐｔｐ-ａｓｅ억제제로서의 그의 용도
BRPI0619543A2 (pt) 2005-12-08 2011-10-04 Novartis Ag derivados de 1,2,5-tiazolidina, composições farmacêuticas contendo os mesmos e referidos usos
US8084448B2 (en) 2006-03-31 2011-12-27 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
TW200732315A (en) 2007-09-01
JP2009519248A (ja) 2009-05-14
KR20080074969A (ko) 2008-08-13
AR056838A1 (es) 2007-10-24
AU2006321905B2 (en) 2011-08-11
PE20100733A1 (es) 2010-10-29
US20080262050A1 (en) 2008-10-23
US7700633B2 (en) 2010-04-20
PT1963292E (pt) 2012-05-10
PL1963292T3 (pl) 2012-07-31
EP1963292A2 (en) 2008-09-03
ZA200804074B (en) 2009-03-25
NZ568243A (en) 2011-07-29
ATE546440T1 (de) 2012-03-15
CN101326173A (zh) 2008-12-17
AU2006321905A1 (en) 2007-06-14
EP1963292B1 (en) 2012-02-22
PE20071031A1 (es) 2007-11-15
MA30202B1 (fr) 2009-02-02
ECSP088506A (es) 2008-07-30
BRPI0619600A2 (pt) 2011-10-11
RU2008127254A (ru) 2010-01-20
TNSN08249A1 (en) 2009-10-30
CR10049A (es) 2008-08-25
CA2629857A1 (en) 2007-06-14
IL191549A0 (en) 2008-12-29
WO2007067615A3 (en) 2007-11-15
UA94724C2 (en) 2011-06-10
WO2007067615A2 (en) 2007-06-14
ES2381280T3 (es) 2012-05-24

Similar Documents

Publication Publication Date Title
NO20083031L (no) Tiadiazolderivater som anti-diabetiske agenter
NO20083030L (no) 1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorer
WO2007115058A3 (en) Thiadiazolidinone inhibitors of ptpase
TNSN08247A1 (en) 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
Cameron et al. Discovery and preclinical characterization of 6-chloro-5-[4-(1-hydroxycyclobutyl) phenyl]-1 H-indole-3-carboxylic acid (PF-06409577), a direct activator of adenosine monophosphate-activated protein kinase (AMPK), for the potential treatment of diabetic nephropathy
BR0308974A (pt) Derivados de 1,1-dioxo-1,2,5-tiazolidina-3-ona 5-substituìdos como inibidores de ptpase 1b
WO2007136603A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007070434A3 (en) Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
Rotili et al. Identification of tri‐and tetracyclic pyrimidinediones as sirtuin inhibitors
TNSN08367A1 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
WO2006058064A3 (en) Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
NO20075731L (no) Inhibitorer av mikrosomalt triglyceridtransferprotein og APO-B-sekresjon
NO20070506L (no) Fremgangsmater og mellomprodukter nyttige for fremstilling av kondenserte heterocykliske kinase inhibitorer.
WO2010074588A3 (en) Pharmaceutical compounds
WO2010001169A3 (en) Chemical compounds 251
BRPI0508144A (pt) derivados de oligossacarìdeos sulfatados composto da fórmula geral; composição farmacêutica ou veterinária seu uso; método para a prevenção ou tratamento pelo uso da mesma
WO2008033562A3 (en) Kinase inhibitor compounds
NO20084396L (no) Kombinasjonsterapi
WO2007149451A3 (en) Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors
EA200701471A1 (ru) Замещённые пиридинильные и пиримидинильные производные, используемые в качестве модуляторов метаболизма и лечение ассоциированных с ним расстройств
MX2009010894A (es) Derivados de 3-hidroquinazolin-4-ona para utilizarse como inhibidores de estearoil-coa-desaturasa.
WO2008024390A3 (en) 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders
Mellini et al. Identification of diketopiperazine-containing 2-anilinobenzamides as potent sirtuin 2 (SIRT2)-Selective inhibitors targeting the “selectivity pocket”, substrate-binding site, and NAD+-Binding site

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application